Senti Biosciences, Inc. (SNTI): Nasdaq/NYSE listing notice — Senti Bio receives Nasdaq deficiency notice for bid price below $1.00 per share

Senti Biosciences, Inc.

Received Nasdaq notice on Aug 7, 2023 for bid price below $1.00 for 30 consecutive days.
Has 180 days until Feb 5, 2024 to regain compliance with Minimum Bid Price Requirement.
To regain compliance, closing bid must be at least $1.00 for 10 consecutive trading days.
Company may consider reverse stock split subject to board and stockholder approval.
Failure to regain compliance could lead to delisting; may appeal or transfer to Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Senti Biosciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

August 7, 2023, Senti Biosciences, Inc. (the “ Company ” or “ Senti Bio ”) received written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive trading days, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), had closed below the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). The Notice has no

View on SEC.gov

Browse all listing & compliance notices →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-23-000102

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.